Each week, Clinical Trials Arena journalists analyse data on patent filings and grants that illustrate innovation trends in our sector. These patent signals show where the leading companies are focusing their research and development investment, and why. We uncover key innovation areas in the sector and the themes that drive them.  

This new thematic patents coverage is powered by our underlying Disruptor data which tracks all major deals, patents, company filings, hiring patterns and social media buzz across our sectors.  

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

This week, we examine GlobalData patent analytics of assignees and therapy trends for patent filings in the pharmaceutics landscape over Q2 2023. In this period, the Chinese Academy of Sciences led the number of patents filed for, with F. Hoffman-La Roche and LG Corp right behind.

The analysis demonstrated that the Beijing, China-based company had 947 total publications, 616 applications and 324 grants, showing prospective revenue streams for them. Grants here refer to approved documents by the patent office after document examination and criteria satisfaction.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Most patents filed were related to severe acute respiratory syndrome (SARS), inflammation, Diabetes, and Alzheimer’s diseases, which show recent trends in clinical trials for these therapy areas.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact